Stockscreener 앱 받기
6.02
4.14%
-0.26
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 - Investing.com Canada
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target - Investing.com Canada
Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Insider Trends: Will Foghorn Therapeutics Inc stock benefit from green energy trendsJuly 2025 Review & Real-Time Stock Movement Alerts - Bộ Nội Vụ
What momentum indicators show for Foghorn Therapeutics Inc. stockJuly 2025 Catalysts & Safe Entry Trade Signal Reports - Улправда
Foghorn Therapeutics Inc. Secures $50 Million in Equity Financing to Advance Oncology Pipeline and Strengthen Balance Sheet - Quiver Quantitative
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - Yahoo Finance
Biotech raises $50M to push new lung and breast cancer drugs forward - Stock Titan
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic ... - Bluefield Daily Telegraph
Will Foghorn Therapeutics Inc. stock benefit from green energy trends - Улправда
Can Foghorn Therapeutics Inc. stock sustain free cash flow growthWeekly Investment Report & High Accuracy Trade Signal Alerts - Улправда
Can Foghorn Therapeutics Inc. stock reach $100 price targetEarnings Beat Highlights & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Why Foghorn Therapeutics Inc. stock is recommended by analystsRisk-Reward Ratio Analysis & Small Budget Big Profits - Улправда
Will Foghorn Therapeutics Inc. stock continue upward momentumBull Market Opportunities & Outstanding Wealth Building - ulpravda.ru
Is Foghorn Therapeutics Inc. stock a bargain at current levels2026 world cup usa national team group stage top scorers possession football odds analysis expert opinion - Улправда
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Can Foghorn Therapeutics Stock Hold Up When Markets Turn? - Trefis
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
BTIG Research Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy" - MarketBeat
Is Foghorn Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Decliners & AI Forecast Swing Trade Picks - bolumsonucanavari.com
How Foghorn Therapeutics Inc. stock performs after earningsJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - Улправда
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
Will Foghorn Therapeutics Inc. stock deliver better than expected guidanceWeekly Stock Recap & Proven Capital Preservation Tips - Улправда
Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - Sahm
BTIG Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
BTIG Research Initiates Coverage on Foghorn Therapeutics With Buy Rating, $11 Price Target - MarketScreener
BTIG Initiates Coverage on FHTX with a Buy Rating and $11.00 Pri - GuruFocus
Support Test: What momentum indicators show for Foghorn Therapeutics Inc. stockPortfolio Return Report & Low Risk Investment Opportunities - Улправда
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) vs. Arcadia Biosciences (NASDAQ:RKDA) Head to Head Analysis - Defense World
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - The Globe and Mail
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
4.73%
0.92%
자본화:
|
볼륨(24시간):